CTCE-0214

Summary

CTCE-0214 is a synthetic peptide analogue of stromal cell‑derived factor‑1α (SDF‑1α) that activates the CXCR4 chemokine receptor. In pre‑clinical studies it has been investigated primarily for its ability to modulate immune and vascular responses in models of sepsis, acute respiratory distress syndrome, and hematopoietic cell mobilization.

Mechanism of Action

CTCE‑0214 binds to CXCR4, mimicking SDF‑1α and triggering downstream signaling cascades such as AKT/Rac‑1 activation and up‑regulation of micro‑RNA‑126. These pathways enhance neutrophil recruitment and phagocytosis, strengthen endothelial barrier integrity, promote endothelial progenitor cell proliferation and angiogenesis, and modulate cytokine production, collectively contributing to reduced inflammation and improved vascular stability.

What the Research Shows

Animal experiments show that CTCE‑0214, administered intravenously or subcutaneously, improves survival in murine sepsis (cecal ligation and puncture) when combined with antibiotics or endothelial progenitor cells, and reduces bacterial loads in blood, peritoneum and lung. The peptide suppresses plasma IL‑6 and TNF‑α in endotoxemia, limits vascular leak and edema in lipopolysaccharide‑induced ARDS, and restores endothelial barrier via miR‑126‑dependent AKT/Rac‑1 signaling. In a xenograft model, CTCE‑0214 mobilizes human colony‑forming cells and enhances thrombopoiesis. In vitro, it augments neutrophil phagocytosis, reactive oxygen species generation, EPC proliferation, and miRNA expression. No human trials have been reported.

Reported Benefits

Pre‑clinical data suggest CTCE‑0214 can (1) boost neutrophil recruitment and bacterial clearance, (2) attenuate systemic inflammatory cytokines such as IL‑6, (3) protect endothelial barrier function and reduce pulmonary edema in ARDS models, (4) synergize with endothelial progenitor cells to improve survival in sepsis, and (5) mobilize hematopoietic progenitors and increase platelet production, indicating potential utility in infectious, vascular, and hematologic contexts.

Limitations of the Evidence

All evidence comes from rodent or xenograft studies; no clinical data exist to confirm efficacy or safety in humans. Reported effects on cytokines are not uniform (TNF‑α suppression varies), and optimal dosing, timing, and formulation remain undefined. The peptide’s antagonist versus agonist classification is inconsistent across sources, reflecting incomplete mechanistic understanding. Translational relevance of murine sepsis and ARDS models to human disease is uncertain.

Safety Considerations

The published animal studies did not report overt toxicity or adverse events associated with CTCT‑0214 at the doses used (e.g., 10 mg/kg subcutaneously or intravenously). However, absence of reported side effects does not guarantee safety, and pharmacokinetic, immunogenicity, or off‑target effects have not been evaluated in humans. Caution is warranted until formal toxicology and clinical safety assessments are performed.

How It Is Administered

In experimental settings CTCE‑0214 has been delivered by subcutaneous or intravenous injection in rodents, typically as a sterile peptide solution. Formulation details (e.g., buffers, excipients) are not described in the cited literature. No oral or other routes have been reported.

Routes of Administration

Goals & Uses

• Myocardial repairCardiovascularModerate
• Stem cell mobilizationHematopoietic Stem Cell TransplantationModerate

Contraindications

• PregnancyPopulationModeratePotential fetal risk or insufficient safety data
• Severe uncontrolled hypertensionCardiovascularHigh

Adverse Effects

• Injection site painLocalCommonPain at the injection site
• Transient hypotensionCardiovascularUncommon

Drug Interactions

• Beta‑blockersModerate

Population Constraints

• Pediatric patientsAgeRelative

Regulatory Status

• European UnionInvestigationalNo marketing authorization granted.
• United StatesInvestigationalPhase I/II clinical trials ongoing.

Evidence & Sources

• Combined treatment with a CXCL12 analogue and antibiotics improves survival and neutrophil recruitment and function in murine sepsis
  Journal ArticleLowGuan S, et al.2014-01-01T00:00:00.000000Z
• The many facets of SDF-1alpha, CXCR4 agonists and antagonists on hematopoietic progenitor cells
  Journal ArticleLowFaber A, et al.2007-01-01T00:00:00.000000Z
• A Stromal Cell-Derived Factor 1α Analogue Improves Endothelial Cell Function in Lipopolysaccharide-Induced Acute Respiratory Distress Syndrome
  Journal ArticleLowGuo C, et al.2016-01-01T00:00:00.000000Z
• Beneficial effect of a CXCR4 agonist in murine models of systemic inflammation
  Journal ArticleLowFan H, et al.2012-01-01T00:00:00.000000Z
• Increased plasma levels of stromal-derived factor-1 (SDF-1/CXCL12) enhance human thrombopoiesis and mobilize human colony-forming cells (CFC) in NOD/SCID mice
  Journal ArticleLowPerez LE, et al.2004-01-01T00:00:00.000000Z
• Endothelial progenitor cells and a stromal cell-derived factor-1α analogue synergistically improve survival in sepsis
  Journal ArticleLowFan H, et al.2014-01-01T00:00:00.000000Z

Frequently Asked Questions